腾盛博药-B(02137)发布年度业绩，股东应占亏损2.23亿元同比收窄56.19%

智通财经03-19

智通财经APP讯，腾盛博药-B(02137)发布截至2025年12月31日止年度业绩，该公司取得收益人民币1860.5万元(单位下同)，去年同期收益为0元;公司拥有人应占年内亏损2.23亿元，同比收窄56.19%;每股亏损0.31元。公告称，收益增加主要归因于根据与健康元集团订立的知识产权许可及技术转让协议所收取的款项。

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2620024498?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-03-19 19:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2620024498","market":"fut","top_or_hot":-1,"title":"腾盛博药-B(02137)发布年度业绩，股东应占亏损2.23亿元 同比收窄56.19%","media":"智通财经","content":"<div>\n<p>智通财经APP讯，腾盛博药-B(02137)发布截至2025年12月31日止年度业绩，该公司取得收益人民币1860.5万元(单位下同)，去年同期收益为0元;公司拥有人应占年内亏损2.23亿元，同比收窄56.19%;每股亏损0.31元。公告称，收益增加主要归因于根据与健康元集团订立的知识产权许可及技术转让协议所收取的款项。</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1416054.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>腾盛博药-B(02137)发布年度业绩，股东应占亏损2.23亿元 同比收窄56.19%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n腾盛博药-B(02137)发布年度业绩，股东应占亏损2.23亿元 同比收窄56.19%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-19 19:04 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1416054.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，腾盛博药-B(02137)发布截至2025年12月31日止年度业绩，该公司取得收益人民币1860.5万元(单位下同)，去年同期收益为0元;公司拥有人应占年内亏损2.23亿元，同比收窄56.19%;每股亏损0.31元。公告称，收益增加主要归因于根据与健康元集团订立的知识产权许可及技术转让协议所收取的款项。</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1416054.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1574","symbol_name":"生物医药B类股","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1416054.html","article_id":"2620024498","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2620024498","pubTimestamp":1773918289,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，腾盛博药-B(02137)发布截至2025年12月31日止年度业绩，该公司取得收益人民币1860.5万元(单位下同)，去年同期收益为0元;公司拥有人应占年内亏损2.23亿元，同比收窄56.19%;每股亏损0.31元。公告称，收益增加主要归因于根据与健康元集团订立的知识产权许可及技术转让协议所收取的款项。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1574":"生物医药B类股","02137":"腾盛博药-B","BK1161":"生物科技","BK1587":"次新股"},"translate_title":"Tengsheng Boyao-B (02137) released its annual results, with a loss attributable to shareholders of 223 million yuan narrowing by 56.19% year-on-year","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02137":1.5},"content_text":"智通财经APP讯，腾盛博药-B(02137)发布截至2025年12月31日止年度业绩，该公司取得收益人民币1860.5万元(单位下同)，去年同期收益为0元;公司拥有人应占年内亏损2.23亿元，同比收窄56.19%;每股亏损0.31元。公告称，收益增加主要归因于根据与健康元集团订立的知识产权许可及技术转让协议所收取的款项。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2620024498","isCrawlerRequest":true}

腾盛博药-B(02137)发布年度业绩，股东应占亏损2.23亿元 同比收窄56.19%

精彩评论

腾盛博药-B(02137)发布年度业绩，股东应占亏损2.23亿元同比收窄56.19%